Wird geladen...
Checkpoint inhibitors in the treatment of urological malignancies
Checkpoint inhibitors are monoclonal antibodies attach to several different receptors on T-cells or tumour cells expressing receptors for cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death-1 (PD-1) and their ligand (PD-L1). Since 2010, numerous trials on different tumour types have been con...
Gespeichert in:
| Veröffentlicht in: | ESMO Open |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BMJ Publishing Group
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5519795/ https://ncbi.nlm.nih.gov/pubmed/28761743 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2017-000165 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|